• Manuel Faria
  • Gilvan Cortês Nascimento
  • André M. Faria
  • Manoel R. A. Martins


Hypopituitarism refers to a complex medical condition characterized by the deficiency of one or more of the hormones of the pituitary gland. Its prevalence is around 45 cases per 100,000 individuals. There are numerous causes of hypopituitarism, with sellar (e.g., pituitary adenoma) and perisellar tumors being the commonest etiologic factors, along with the sequelae generated by the different therapeutical modalities employed towards its resolution, such as surgery and radiotherapy. Clinical presentation may have a broad spectrum depending on cause and age of onset, and may vary from chronic/subacute nonspecific general ill feeling and mass effect related symptoms, as it commonly occurs with space-occupying sellar masses, to an acute and life-threatening presentation, such as that seen in pituitary apoplexy. Diagnostic approaches towards identifying the etiologic factors and each hormonal axis deficiency (i.e., GH, LH/FSH, TSH, ACTH, and ADH), as well as the description of the different available schemes of hormone replacement therapy, are thoroughly reviewed in this chapter.


Growth Hormone Growth Hormone Therapy Pituitary Apoplexy Growth Hormone Replacement Central Hypothyroidism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Regal M, et al. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf). 2001;55(6):735–40.CrossRefGoogle Scholar
  2. 2.
    van Aken MO, Lamberts SW. Diagnosis and treatment of hypopituitarism: an update. Pituitary. 2005;8(3–4):183–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Toogood AA, Stewart PM. Hypopituitarism: clinical features, diagnosis, and management. Endocrinol Metab Clin North Am. 2008;37(1):235–61. x.PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes NR, Lissett CA, Shalet SM. Growth hormone status following treatment for Cushing’s syndrome. Clin Endocrinol (Oxf). 1999;51(1):61–6.CrossRefGoogle Scholar
  5. 5.
    Prabhakar VK, Shalet SM. Aetiology, diagnosis, and management of hypopituitarism in adult life. Postgrad Med J. 2006;82(966):259–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Carroll PV, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83(2):382–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Bhasin S, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.PubMedCrossRefGoogle Scholar
  8. 8.
    Bin-Abbas B, et al. Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. J Pediatr. 1999;134(5):579–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Alexopoulou O, et al. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol. 2004;150(1):1–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Fenske W, Allolio B. Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab. 2012;97:3426–37.PubMedCrossRefGoogle Scholar
  12. 12.
    Rosenfeld RG, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab. 1995;80(5):1532–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Richmond EJ, Rogol AD. Growth hormone deficiency in children. Pituitary. 2008;11(2):115–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Martha Jr PM, et al. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab. 1989;69(3):563–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Bhala A, et al. Insulin-like growth factor axis parameters in sick hospitalized neonates. J Pediatr Endocrinol Metab. 1998;11(3):451–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Strasburger CJ, Bidlingmaier M. How robust are laboratory measures of growth hormone status? Horm Res. 2005;64 Suppl 2:1–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Gandrud LM, Wilson DM. Is growth hormone stimulation testing in children still appropriate? Growth Horm IGF Res. 2004;14(3):185–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990–3.CrossRefGoogle Scholar
  19. 19.
    Lanes R, Hurtado E. Oral clonidine-an effective growth hormone-releasing agent in prepubertal subjects. J Pediatr. 1982;100(5):710–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Sandra P, Popovic V. Diagnosis of growth hormone deficiency in adults. In: Ho K, editor. Growth hormone related diseases and therapy: a molecular and physiological perspective for the clinician. New York, NY: Springer Science + business Media; 2011.Google Scholar
  21. 21.
    Leong KS, et al. An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clin Endocrinol (Oxf). 2001;54(4):463–8.CrossRefGoogle Scholar
  22. 22.
    Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–609.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee P, Greenfield JR, Ho KK. Factors determining inadequate hypoglycaemia during insulin tolerance testing (ITT) after pituitary surgery. Clin Endocrinol (Oxf). 2009;71(1):82–5.CrossRefGoogle Scholar
  24. 24.
    Ghigo E, et al. Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. Metabolism. 1992;41(9):1000–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Corneli G, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol. 2005;153(2):257–64.PubMedCrossRefGoogle Scholar
  26. 26.
    Darzy KH, et al. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH deficiency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab. 2003;88(1):95–102.PubMedCrossRefGoogle Scholar
  27. 27.
    Clayton PE, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol. 2005;152(2):165–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Corneli G, et al. Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol. 2007;157(6):701–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Maghnie M, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol. 2005;152(4):589–96.PubMedCrossRefGoogle Scholar
  30. 30.
    Oliveira JH, et al. Investigating the paradox of hypothyroidism and increased serum thyrotropin (TSH) levels in Sheehan’s syndrome: characterization of TSH carbohydrate content and bioactivity. J Clin Endocrinol Metab. 2001;86(4):1694–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Behan LA, Monson JP, Agha A. The interaction between growth hormone and the thyroid axis in hypopituitary patients. Clin Endocrinol (Oxf). 2011;74(3):281–8.CrossRefGoogle Scholar
  32. 32.
    Portes ES, et al. Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children. Clin Endocrinol (Oxf). 2000;53(2):183–9.CrossRefGoogle Scholar
  33. 33.
    Doin FC, et al. Diagnosis of subclinical central hypothyroidism in patients with hypothalamic-pituitary disease by Doppler echocardiography. Eur J Endocrinol. 2012;166(4):631–40.PubMedCrossRefGoogle Scholar
  34. 34.
    Faglia G. The clinical impact of the thyrotropin-releasing hormone test. Thyroid. 1998;8(10):903–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Mehta A, et al. Is the thyrotropin-releasing hormone test necessary in the diagnosis of central hypothyroidism in children. J Clin Endocrinol Metab. 2003;88(12):5696–703.PubMedCrossRefGoogle Scholar
  36. 36.
    Wallace I, Cunningham S, Lindsay J. The diagnosis and investigation of adrenal insufficiency in adults. Ann Clin Biochem. 2009;46(Pt 5):351–67.PubMedCrossRefGoogle Scholar
  37. 37.
    Thaler LM, Blevins Jr LS. The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab. 1998;83(8):2726–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003;139(3):194–204.PubMedCrossRefGoogle Scholar
  39. 39.
    Molitch ME. Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):667–75.PubMedCrossRefGoogle Scholar
  40. 40.
    Maiya B, et al. Magnetic resonance imaging changes in the pituitary gland following acute traumatic brain injury. Intensive Care Med. 2008;34(3):468–75.PubMedCrossRefGoogle Scholar
  41. 41.
    Schneider HJ, et al. Pituitary imaging abnormalities in patients with and without hypopituitarism after traumatic brain injury. J Endocrinol Invest. 2007;30(4):RC9–12.PubMedGoogle Scholar
  42. 42.
    Wit JM. Growth hormone therapy. Best Pract Res Clin Endocrinol Metab. 2002;16(3):483–503.PubMedCrossRefGoogle Scholar
  43. 43.
    Mauras N, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab. 2000;85(10):3653–60.PubMedCrossRefGoogle Scholar
  44. 44.
    Reiter EO, et al. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab. 2006;91(6):2047–54.PubMedCrossRefGoogle Scholar
  45. 45.
    Cutfield WS, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355(9204):610–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Cohen P, et al. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab. 2010;95(5):2089–98.PubMedCrossRefGoogle Scholar
  47. 47.
    Ranke MB, Lindberg A. Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95(3):1229–37.PubMedCrossRefGoogle Scholar
  48. 48.
    Thuesen L, et al. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol (Oxf). 1994;41(5):615–20.CrossRefGoogle Scholar
  49. 49.
    Tomlinson JW, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357(9254):425–31.PubMedCrossRefGoogle Scholar
  50. 50.
    Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMedCrossRefGoogle Scholar
  51. 51.
    Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–27.PubMedCrossRefGoogle Scholar
  52. 52.
    Mah PM, et al. Estrogen replacement in women of fertile years with hypopituitarism. J Clin Endocrinol Metab. 2005;90(11):5964–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Menon DV, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat Endocrinol. 2006;5(1):37–51.PubMedCrossRefGoogle Scholar
  54. 54.
    Leung KC, et al. Estrogen regulation of growth hormone action. Endocr Rev. 2004;25(5):693–721.PubMedCrossRefGoogle Scholar
  55. 55.
    Kiess W, et al. Induction of puberty in the hypogonadal girl–practices and attitudes of pediatric endocrinologists in Europe. Horm Res. 2002;57(1–2):66–71.PubMedCrossRefGoogle Scholar
  56. 56.
    Ankarberg-Lindgren C, et al. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab. 2001;86(7):3039–44.PubMedCrossRefGoogle Scholar
  57. 57.
    Ascoli P, Cavagnini F. Hypopituitarism. Pituitary. 2006;9(4):335–42.PubMedCrossRefGoogle Scholar
  58. 58.
    Schurmeyer T, et al. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol (Copenh). 1983;102(3):456–62.Google Scholar
  59. 59.
    Schulte-Beerbuhl M, Nieschlag E. Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil Steril. 1980;33(2):201–3.PubMedGoogle Scholar
  60. 60.
    Schubert M, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 2004;89(11):5429–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol. 2000;161(1–2):73–88.PubMedCrossRefGoogle Scholar
  62. 62.
    Jordan Jr WP. Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am J Contact Dermat. 1997;8(2):108–13.PubMedCrossRefGoogle Scholar
  63. 63.
    Swerdloff RS, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500–10.PubMedCrossRefGoogle Scholar
  64. 64.
    Wang C, et al. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf). 2011;75(6):836–43.CrossRefGoogle Scholar
  65. 65.
    Dobs AS, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl. 2012;33(4):601–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Meikle AW, et al. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. J Clin Endocrinol Metab. 1996;81(5):1832–40.PubMedCrossRefGoogle Scholar
  67. 67.
    Wang C, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004;89(8):3821–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Jockenhovel F, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf). 1996;45(1):61–71.CrossRefGoogle Scholar
  69. 69.
    Vicari E, et al. Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotrophic hypogonadism–long-term follow-up. Int J Androl. 1992;15(4):320–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Yamada M, Mori M. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat Clin Pract Endocrinol Metab. 2008;4(12):683–94.PubMedCrossRefGoogle Scholar
  71. 71.
    Martins MR, et al. Growth hormone replacement improves thyroxine biological effects: implications for management of central hypothyroidism. J Clin Endocrinol Metab. 2007;92(11):4144–53.PubMedCrossRefGoogle Scholar
  72. 72.
    Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):217–23.PubMedCrossRefGoogle Scholar
  73. 73.
    Arlt W, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab. 1998;83(6):1928–34.PubMedCrossRefGoogle Scholar
  74. 74.
    Bilger M, et al. Androgen replacement in adolescents and young women with hypopituitarism. J Pediatr Endocrinol Metab. 2005;18(4):355–62.PubMedCrossRefGoogle Scholar
  75. 75.
    Johannsson G, et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002;87(5):2046–52.PubMedCrossRefGoogle Scholar
  76. 76.
    van Thiel SW, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab. 2005;90(6):3295–303.PubMedCrossRefGoogle Scholar
  77. 77.
    Libe R, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest. 2004;27(8):736–41.PubMedGoogle Scholar
  78. 78.
    Lovas K, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab. 2003;88(3):1112–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Alkatib AA, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3676–81.PubMedCrossRefGoogle Scholar
  80. 80.
    Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23(2):167–79.PubMedCrossRefGoogle Scholar
  81. 81.
    Schneider HJ, et al. Hypopituitarism. Lancet. 2007;369(9571):1461–70.PubMedCrossRefGoogle Scholar
  82. 82.
    Filipsson H, Johannsson G. GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol. 2009;161 Suppl 1:S85–95.PubMedCrossRefGoogle Scholar
  83. 83.
    Giavoli C, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab. 2004;89(11):5397–401.PubMedCrossRefGoogle Scholar
  84. 84.
    Giavoli C, et al. Effect of growth hormone deficiency and recombinant hGH (rhGH) replacement on the hypothalamic-pituitary-adrenal axis in children with idiopathic isolated GH deficiency. Clin Endocrinol (Oxf). 2008;68(2):247–51.Google Scholar
  85. 85.
    Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999;84(11):3956–60.PubMedCrossRefGoogle Scholar
  86. 86.
    Castinetti F, et al. Pituitary stem cell update and potential implications for treating hypopituitarism. Endocr Rev. 2011;32(4):453–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Manuel Faria
    • 1
  • Gilvan Cortês Nascimento
    • 1
  • André M. Faria
    • 2
  • Manoel R. A. Martins
    • 3
  1. 1.Department of Internal Medicine I, Service of Endocrinology and MetabolismHospital Universitário Presidente Dutra, Federal University of MaranhãoSão LuísBrazil
  2. 2.Division of Endocrinology and MetabolismHospital das Clínicas, University of São Paulo Medical SchoolSão PauloBrazil
  3. 3.Department of Clinical MedicineHospital Universitário Walter Cantídio, Federal University of CearáFortalezaBrazil

Personalised recommendations